Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A

INTRODUCTION: Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94–9027, Jivi, Bayer, Germany) is a site-specifically PEGylated, extended-half-life, recombinant FVIII, approved for use in previously treated patients (PTPs) aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanabria, Martin, Álvarez Román, María Teresa, Castaman, Giancarlo, Janbain, Maissaa, Matsushita, Tadashi, Meijer, Karina, Oldenburg, Johannes, Friedl, Sabine, Reding, M T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413870/
https://www.ncbi.nlm.nih.gov/pubmed/34475142
http://dx.doi.org/10.1136/bmjopen-2020-044997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413870/
https://www.ncbi.nlm.nih.gov/pubmed/34475142
http://dx.doi.org/10.1136/bmjopen-2020-044997

Ejemplares similares